Drug and Therapeutics Bulletin 1997;35:57-58; doi:10.1136/dtb.1997.35857
Copyright © 1997 by the BMJ Publishing Group Ltd.
Humalog - a new insulin analogue
Relevant BNF section: 6.1.1.1
Insulin lispro (Humalog - Lilly) is a genetically engineered human insulin analogue which the manufacturer claims to allow patients "the convenience of injecting immediately before they eat". It is licensed for the treatment of patients who require insulin therapy for maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus. Here we review insulin lispro and assess its place in the treatment of patients with diabetes.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
